S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes

Annals of Hematology

Volumn 74, Issue 5, 1997, Pages 205-208

  Verbeek, W ^a,g   Wormann B ^a   Koch, P ^b   Aul, C ^c   Hinrichs, H ^d   Balleisen, L ^e   Rowe, J M ^f   Bennett, J ^f   Buchner T ^b   Hiddemann, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d Evangelisches Krankenhaus   (Germany)

^e EVANGELISCHES KRANKENHAUS   (Germany)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

GM CSF; High dose cytosine arabinoside; Myelodysplastic syndromes

Indexed keywords

CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CAUSE OF DEATH; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HEMATOPOIESIS; HUMAN; INFECTIOUS COMPLICATION; MALE; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPERGILLUS; BLOOD; CANDIDA; CENTRAL NERVOUS SYSTEM DISEASES; CYTARABINE; DOUBLE-BLIND METHOD; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; MITOXANTRONE; MYELODYSPLASTIC SYNDROMES; RISK FACTORS;

EID: 1842290990     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050285     Document Type: Article

References (19)

1. Anderson JE, Appelbaum FR, Fisher LD, Shulman H, Schoch G, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Doney K, Martin PJ, Sanders JE, Sullivan KM, Thomas ED, Witherspoon RP, Hansen JA, Storb R (1993) Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677-681
2. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52-59
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) The French-American-British-Group: proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
4. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber Ch, Haas O, Vieder L, Maurer D, Schulz G, Speiser W, Geissler K, Kier P, Hinterberger W, Lechner K (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700-711
5. Bernell P, Kimby E, Hast R (1994) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia 8:1631-1639
6. Büchner T, Hiddemann W, Koenigsmann M, Zùhlsdorf M, Wörmann B, Boeckmann A, Aguion-Freire E, Innig G, Maschmeyer G, Ludwig WD, Sauerland M, Heinecke A, Schulz G (1991) Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190-1197
7. De Witte T (1994) New treatment approaches for myelodysplastic syndromes and secondary leukaemias. Ann Oncol 5:401-408
8. De Witte T, Muus P, De Paw (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831-837
9. De Witte T, Suciu S, Peetermann M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, Solbu G, Zwierzina H, Muus P (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9:1805-1811
10. Economopoulos T, Papageorgiou E, Stathakis N, Constantinidou M, Parharidou A, Kostourou A, Dervenoulas J, Raptis S (1996) Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leukemia Res 20:385-390
11. Fenaux P, Morell P, Rose C, Lai JL, Jouet JP, Bauters F (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated with intensive chemotherapy. Br J Haematol 77:497-501
12. Hamblin TJ (1992) Intensive chemotherapy in myelodysplastic syndromes. Blood Rev 3:215-219
13. Hiddemann W (1991) Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol 62:119-128
14. Hiddemann W. Aul C, Maschmeyer G, Schönrock-Nabulsi, Ludwig WD, Bartholomäus A, Bettelheim P, Becker K, Balleisen L, Lathan B, Köppler H, Grüneisen T, Donhuijsen-Ant, Reichte A, Heinecke A, Sauerland C, Büchner T (1993) High dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: Results of an age adjusted randomized comparison. Leukemia Lymphoma 10:133-137
15. Hirst WJR, Mufti GJ (1994) The rate of disease progression predicts the quality of remission following intensive chemotherapy for myelodysplastic syndromes. Leukemia Res 18:797-804
16. Michels SD, Saumur J, Arthur DC, Robison LL, Brunning RD (1989) Refractory anemia with excess of blasts in transformation: hematologic and clinical study of 52 patients. Cancer 64:2340-2346
17. Preisler HD, Raza M, Barcos M (1986) High dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study. Am J Hematol 23:131-134
18. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Walker I, Browmann M, Grunwald H, D'Arrigo P, Doeblin T (1987) High dose cytosine arabinoside as the initial treatment of poor risk patients with acute non-lymphocytic leukemia: a leukemia intergroup a study. J Clin Oncol 5:75-82
19. Tricot G, De Bock R, Dekker AW (1986) The role of aggressive chemotherapy in the treatment of myelodysplastic syndromes. Br J Haematol 63:477-483